Completed
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
NCT02017613
- Conditions
- Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
- Locations
-
- Rhizen Trial Site Paris, France
- Rhizen Trial Site 1 Milan, Italy
- Rhizen Trial Site 2 Milan, Italy